<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04380077</url>
  </required_header>
  <id_info>
    <org_study_id>IRB0009239-Retina 5</org_study_id>
    <nct_id>NCT04380077</nct_id>
  </id_info>
  <brief_title>Gas Tamponade for Prevention of Postoperative Vitreous Hemorrhage in Diabetics</brief_title>
  <official_title>Gas Tamponade for Prevention of Postoperative Vitreous Hemorrhage in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush Eye Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush Eye Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Patients undergoing pars plana vitrectomy for the indication of diabetic vitreous&#xD;
      hemorrhage will have a lower incidence of postoperative vitreous hemorrhaging during the&#xD;
      6-month trial period when vitreous substitution with 20-30% sulfur hexafluoride gas is&#xD;
      utilized compared to vitreous substitution with balanced salt solution.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects enrolled into the study are randomized into one of the ensuing treatment cohorts:&#xD;
      Group A patients undergo vitreous substitution with 20-30% sulfur hexafluoride (SF6) gas&#xD;
      during PPV, whereas Group B patients undergo vitreous substitution with balanced salt&#xD;
      solution (BSS) during PPV. Simple randomization allocates patients into treatment groups&#xD;
      during PPV. Once all relevant maneuvers are completed by the surgeon prior to vitreous&#xD;
      substitution, a simulated coin toss program decides the vitreous substitute, and therefore&#xD;
      which group the patient enters. Randomization intraoperatively mitigates against selection&#xD;
      bias of utilized surgical maneuvers such as endodiathermy on the part of the surgeon and&#xD;
      allows for subjects to not undergo randomization in cases where intraoperative retinal breaks&#xD;
      occur that would preclude the subject from receiving vitreous substitution with BSS.&#xD;
&#xD;
      Subjects undergo data collection at 3 postoperative visits: 1) 15 +/- 5 days following PPV,&#xD;
      2) 40 +/- 10 days following PPV, and 3) 185 +/- 15 days following PPV. Study subjects are&#xD;
      evaluated at non-study times at the judgment of the examiner.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 15, 2020</start_date>
  <completion_date type="Anticipated">January 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 21, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>The operating surgeons did not participate in the preoperative or postoperative care of the patient, including the data collection.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative vitreous hemorrhage rate</measure>
    <time_frame>6 months</time_frame>
    <description>incidence of postoperative vitreous hemorrhage between cohorts</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>unplanned vitrectomy rate</measure>
    <time_frame>6 months</time_frame>
    <description>unplanned vitrectomy for the indication of postoperative vitreous hemorrhage between cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Snellen best-corrected visual acuity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>SF6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitreous substitution with 20-30% sulfur hexafluoride gas during vitrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vitreous substitution with balances salt solution during vitrectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>vitrectomy with sulfur hexafluoride gas</intervention_name>
    <description>vitreous substitution with 20-30% sulfur hexafluoride gas during vitrectomy</description>
    <arm_group_label>SF6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>vitrectomy with balanced salt solution</intervention_name>
    <description>vitreous substitution with balances salt solution during vitrectomy</description>
    <arm_group_label>Fluid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          1. The patient has medically-managed type I or II diabetes mellitus.&#xD;
&#xD;
          2. The age of the patient is &gt; 18 years old,&#xD;
&#xD;
          3. Snellen best-corrected visual acuity is from 20/40 to hand motions at one foot in the&#xD;
             subject's study eye&#xD;
&#xD;
          4. Proliferative diabetic retinopathy with a clinically evident vitreous hemorrhage of&#xD;
             duration of at least one month by subjective history is present in the subject's study&#xD;
             eye.&#xD;
&#xD;
          5. The vitreous hemorrhage is symptomatic and primarily responsible for the patient's&#xD;
             reduced vision in the judgement of the examiner.&#xD;
&#xD;
          6. Grade 0 or I vitreoretinal adhesion according to the classification system described&#xD;
             by Ahn et al [@] in the study eye is clinically present.&#xD;
&#xD;
               -  Ahn J, Woo SJ, Chung H, et al. The effect of adjunctive intravitreal bevacizumab&#xD;
                  for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy.&#xD;
                  Ophthalmology. 2011; 118: 2218-2226.&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          1. The subject's study eye previously underwent anterior or posterior vitrectomy.&#xD;
&#xD;
          2. A lens or cornea opacity is thought to be responsible for two or more lines of reduced&#xD;
             visual acuity in the subject's study eye (cataract, corneal scar, ectasia, etc.).&#xD;
&#xD;
          3. Optic nerve or retina disease otherwise not related to diabetes mellitus is thought to&#xD;
             be responsible for two or more lines of reduced visual acuity in the subject's study&#xD;
             eye (optic neuritis, macular degeneration, glaucoma, epiretinal membrane, etc.).&#xD;
&#xD;
          4. A non-ocular cause (i.e. cerebrovascular accident) or amblyopia is thought to be&#xD;
             responsible for two or more lines of reduced visual acuity in the subject's study eye&#xD;
&#xD;
          5. Neovascular glaucoma with a high intraocular pressure ( &gt; 30 mm Hg) is discovered in&#xD;
             the subject's study eye.&#xD;
&#xD;
          6. Medically uncontrolled systemic hypertension (systolic &gt; 200 mmHg or diastolic &gt; 120&#xD;
             mmHg) is present.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>La Carlota Hospital</name>
      <address>
        <city>Montemorelos</city>
        <state>Nuevo Leon</state>
        <zip>67512</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rush Eye Associates</investigator_affiliation>
    <investigator_full_name>Sloan W. Rush, MD</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Vitreous Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

